

Correction: Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study

Chase D, Huang HQ, Monk BJ, *et al.* Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. *Int J Gynecol Cancer* 2020;30(5):596–601.

Since the online publication of this article, the authors have noticed that their funding statement is incorrect. The correct funding statement is 'This study was supported by NIH grants to NRG Oncology (1U10CA180822), NRG Operations (U10CA180868) and NIH NCORP grant (UG1CA189867).'

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Int J Gynecol Cancer 2020;30:1267. doi:10.1136/ijgc-2019-000869corr1

